ArticleCureus2026
Dynamic Procalcitonin Trajectories Predict Adverse Outcomes in Acute-on-Chronic Pancreatitis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Acute-on-chronic pancreatitis (ACP) is an increasingly recognized clinical entity associated with significant morbidity, prolonged hospitalization, and increased intensive care utilization. Early identification of high-risk patients remains challenging because conventional prognostic scoring systems are often time-consuming, complex, or insufficiently validated in ACP. Procalcitonin (PCT), a rapid inflammatory biomarker, has demonstrated prognostic utility in acute pancreatitis. However, evidence regarding its role in ACP remains limited. This study aimed to evaluate serial serum PCT levels in hospitalized patients with ACP from Northeast India. Methods This prospective observational study was conducted over one year at a tertiary care center and included 58 adult patients diagnosed with ACP based on the revised Atlanta classification criteria and imaging evidence of chronic pancreatitis (CP). Serial serum PCT levels were measured at admission and 48 hours later. Clinical outcomes, including mortality, ICU admission, organ dysfunction, local complications, and duration of hospitalization, were analyzed. Receiver operating characteristic (ROC) curve analysis was performed to assess the prognostic accuracy of PCT. Results Severe clinical outcomes were common, with mortality observed in 12.1% (n = 7) of patients, ICU admission in 60.3% (n = 35), and local pancreatic complications noted among 82.8% (n = 48) of the cases. Admission PCT demonstrated poor prognostic performance for mortality prediction (area under the curve (AUC): 0.555), with a sensitivity of 46.9% at a cutoff of 3.46 ng/mL. In contrast, 48-hour PCT showed excellent predictive accuracy, yielding an AUC of 0.992. A threshold value of 4.04 ng/mL achieved 100% sensitivity and 100% negative predictive value (NPV) for mortality prediction. Elevated PCT levels were significantly associated with ICU admission (p = 0.034), organ dysfunction (p = 0.021), local complications (p = 0.041), and prolonged hospitalization (r > 0.95). Conclusions Serial serum PCT assessment, particularly at 48 hours, is a reliable prognostic biomarker in ACP and may facilitate early risk stratification, optimized critical care allocation, and individualized clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.